Marcy l’Étoile (France), April 11th, 2022 – bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the three months ended March 31th, 2022.
- First-quarter organic growth of -4.5% at constant exchange rates and scope of consolidation:
- €837 million in sales
- Down 0.9% as reported
- Solid +6% growth in Industrial Applications and +5% growth in Microbiology
- Stable sales of BIOFIRE® panels, in line with expectations for the quarter
- Anticipated headwinds in Immunoassays with lower COVID-related assays demand
“In a continued highly uncertain business environment, our first quarter performance is aligned with our outlook. Sales growth was particularly solid in both microbiology and industrial applications, and in line with our expectations on molecular biology and immunoassays.”
Read the full press release
- Filename
- 20220411PR - bioMérieux - Sales Q1 2022.pdf
- Size
- 352 KB
- Format
- application/pdf